Moderna's Market Reaction: Understanding the Sell-the-News Phenomenon After Positive Trial Results
Despite positive trial results, Moderna's stock dropped 7.32%, highlighting the sell-the-news trend in biotech.
Merck and Moderna's mRNA Cancer Vaccine Shows Promise in Phase 3 Trials
Merck and Moderna's mRNA-based cancer vaccine for melanoma shows strong Phase 3 trial results, signa…
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's recent FDA approval for an Alzheimer's blood test signals a pivotal moment in diagnostic…
Booz Allen Hamilton Strengthens Defense Sector with Ultra I&C Acquisition
Booz Allen Hamilton (BAH) completes acquisition of Ultra I&C, bolstering its defense technology capa…
Merck and Moderna's Phase 3 Success: A Milestone in Cancer Vaccination
Merck and Moderna report significant success in their Phase 3 trial, reinforcing the role of KEYTRUD…
Eli Lilly's FDA Approval: A Game Changer for Alzheimer's Diagnostics
Eli Lilly's FDA approval for an Alzheimer's blood test could reshape the diagnostics landscape and b…
TG Therapeutics on the Rise: Exploring the Potential of Takeover Speculation
TG Therapeutics gains traction amid takeover rumors, reflecting broader M&A interest in the pharmace…
Impact of U.S.-Canada Trade Talks Collapse on Market Dynamics: What Investors Need to Know
The collapse of U.S.-Canada trade talks and new tariffs raise concerns for investors. Here's what yo…
Moderna's Cancer Vaccine Breakthrough: Implications for Investors and Biotech Traders
The recent Phase 3 trial results for Moderna's cancer vaccine have sent shockwaves through the biote…
Bunker Hill Mining and Silver47 Merger: A New Player in Critical Minerals
Bunker Hill Mining and Silver47 Exploration unite in a $163M all-stock deal, reshaping the critical …